Scarica l'app Stockscreener
6.54
2.39%
-0.16
Dopo l'orario di chiusura:
6.54
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AURA Giù?
Forum
Previsione
Aura Biosciences Inc Borsa (AURA) Ultime notizie
Quarterly Recap: Does Aura Biosciences Inc outperform in volatile markets2026 Dividend Review & Low Risk Investment Opportunities - baoquankhu1.vn
Aura Biosciences (NASDAQ:AURA) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Non Muscle Invasive Bladder Cancer Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Incyte Corp - Barchart
Non Muscle Invasive Bladder Cancer Pipeline 2026: Key - openPR.com
Wall Street analysts predict a 201.49% upside in Aura Biosciences (AURA): Here's what you should know - MSN
Research Analysts Offer Predictions for AURA FY2030 Earnings - Defense World
Wall Street experts forecast a potential 201.49% increase for Aura Biosciences (AURA): Key information you need to know - Bitget
Wall Street Analysts Predict a 201.49% Upside in Aura Biosciences (AURA): Here's What You Should Know - sharewise.com
FY2030 Earnings Forecast for AURA Issued By HC Wainwright - MarketBeat
H.C. Wainwright reiterates Aura Biosciences stock rating at buy By Investing.com - Investing.com Canada
Aura Biosciences Reports 2025 Results, Advances Bel-Sar Pipeline - TipRanks
Aura Biosciences (NASDAQ:AURA) Earns Buy Rating from HC Wainwright - MarketBeat
Aura Biosciences Reports 2025 Financial Results and Advances Phase 3 CoMpass Trial for Choroidal Melanoma - minichart.com.sg
Aura Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Aura Biosciences 10-K: $0 Revenue, $(106.2)M Net Loss - TradingView
Aura Biosciences (NASDAQ:AURA) Issues Earnings Results - MarketBeat
Bel-sar pipeline data and cash risks in Aura Biosciences (NASDAQ: AURA) 10-K - Stock Titan
Aura Biosciences 2025 net loss widens as R&D costs rise - TradingView
Aura Biosciences (NASDAQ: AURA) details 2025 loss, cash runway to Q1 2027 and bel-sar trial timelines - Stock Titan
BRIEF-Aura Biosciences FY Operating Expenses USD 112.791 Million - TradingView
Aura says eye melanoma Phase 3 enrollment now points to 2027 data - Stock Titan
Aura Biosciences, Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
(AURA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Earnings Update: Is Aura Biosciences Inc exposed to currency risksForecast Cut & Advanced Technical Signal Analysis - baoquankhu1.vn
Aura Biosciences, Inc. (NASDAQ:AURA) Given Average Rating of "Hold" by Brokerages - MarketBeat
Is Aura Biosciences (AURA) outperforming other medical stocks this year? - MSN
What makes Aura Biosciences (AURA) a new buy stock - msn.com
Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Bear Alert: Is Aura Biosciences Inc stock undervalued right nowMarket Weekly Review & Technical Buy Zone Confirmation - baoquankhu1.vn
Aura Biosciences (AURA) to Release Earnings on Monday - MarketBeat
Aura Biosciences Posts Q2 Cash Surge - AOL.com
Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Update - MarketBeat
Aura Biosciences Eyes Phase 3 Enrollment Milestone, Reaffirms Q4 2027 Melanoma Data Timeline - Yahoo Finance
Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Sahm
AURA: Phase 3 ocular oncology drug nears enrollment completion, with pivotal data expected in Q4 2027 - TradingView
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Aug Sectors: Is Aura Biosciences Inc stock undervalued right now2025 Investor Takeaways & Reliable Price Breakout Signals - baoquankhu1.vn
Why (AURA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Aura Biosciences Touts Phase 3 bel-sar Momentum, Eyes Mid-Year Bladder Cancer Data at TD Cowen Conference - MarketBeat
AURA: Late-stage oncology programs show strong safety, efficacy, and market potential, with key data ahead - TradingView
Aura's Bel-sar — One Asset, Multiple Oncology Opportunities - RTTNews
Is Assertio (ASRT) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Is Assertio (ASRT) Surpassing Other Healthcare Stocks in Performance This Year? - Bitget
Aura Biosciences (AURA) officer granted RSUs and 112,661-share option - Stock Titan
Aura Biosciences (AURA) officer receives RSU and option grants - Stock Titan
Large equity awards to Elisabet de los Pinos at Aura Biosciences (AURA) - Stock Titan
Aura Biosciences (AURA) CTO receives new stock option and RSU awards - Stock Titan
Aura Biosciences (AURA) grants stock options and RSUs to its CMO - Stock Titan
Aura Biosciences (AURA) SVP awarded 80,472 options and 44,528 RSUs - Stock Titan
Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Wall Street Recap: Is Aura Biosciences Inc in a long term uptrend2025 Technical Overview & Risk Managed Investment Strategies - baoquankhu1.vn
Aura Biosciences, Inc. (AURA) Stock Analysis: A Biotech Gem With 235% Potential Upside - DirectorsTalk Interviews
AURA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aura Biosciences to Participate in Upcoming Investor Conferences - GlobeNewswire
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):